• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Canine myxomatous mitral valve heart disease: When to medicate?

February 7, 2018
Jennifer L. Garcia, DVM, DACVIM

A new study shows that intervention with pimobendan may be helpful in asymptomatic dogs with structural cardiac changes.

Shutterstock.com

Myxomatous mitral valve disease (MMVD) is the leading cause of cardiovascular disease in dogs1,2 and our knowledge of this disease and how to treat it continues to evolve. Despite development of new drugs and treatment regimens, uncertainty remains about when to treat and what the best interventions are for some of these patients.

In 2009, a more objective classification system to categorize patients' heart disease was introduced and helped make treatment decisions easier.3 It is based on patient risk factors and clinical and diagnostic imaging signs:3

Stage A: Patients with no current structural heart disorder (e.g. no heart murmur) but that are high risk for developing heart disease (e.g. Cavalier King Charles Spaniels)

Stage B: Patients with structural cardiac changes (e.g. a heart murmur) but that are asymptomatic

  • Stage B1: No radiographic or echocardiographic evidence of heart disease

  • Stage B2: Radiographic or echocardiographic evidence of left-sided cardiomegaly

Stage C: Patients with current or past history of heart failure and evidence of structural heart disease

Stage D: Patients with end-stage heart failure that is refractory to standard therapy.

Advertisement

New data on intervention

Despite this information on categorizing heart disease severity, there had been little evidence to support the utility of medical intervention for patients with Stage B disease. However, in 2016, the results of a large prospective, randomized, placebo-controlled, blinded clinical trial to evaluate pimobendan treatment in dogs with Stage B2 disease were published.4 In the “Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly” trial, or the EPIC trial for short, 360 client-owned dogs with Stage B2 MMVD were assigned to receive either 0.4 –  to 0.6 mg/kg/day (total dose divided into two administrations given about 12 hours apart) of pimobendan or placebo.4 The goal of the study was to determine if treatment with pimobendan would delay the onset of signs of left-sided congestive heart failure (CHF), euthanasia for a cardiac reason or death presumed to be cardiac in origin.4

To be included in the study, dogs had to:

  • Be at least 6 years of age or older

  • Have a body weight ≥ 4.1 kg and ≤ 15 kg

  • Have at least a grade 3/6 heart murmur with the point of maximal intensity over the mitral valve

  • Have radiographic evidence of cardiomegaly defined as a VHS > 10.5

  • Have echocardiographic evidence of mitral valvular lesions and regurgitation as well as evidence of left atrial and left ventricular dilatation, defined as left atrial to aortic root ratio ≥ 1.6 and body weight normalized left ventricular internal diameter in diastole ≥ 1.7

Dogs receiving other cardiac medications (e.g. angiotensin-converting enzyme inhibitors, diuretics and many others) were excluded from enrollment. Dogs that received these medications during the study for less than five days (if sedation or anesthesia was required), or for less than three days (in the event of inadvertent administration) remained eligible to be included in the final analysis. Dogs were evaluated at one month and then every four months for the duration of the trial.

The study authors found that dogs with Stage B2 MMVD treated with pimobendan took 462 days (15 months) longer to develop CHF or die from MMVD than dogs receiving placebo. In other words, pimobendan prolonged their preclinical stage by 60%. Gastrointestinal side effects were minimal and noted with similar prevalence between the two groups.

What does this mean? 

Data from this Boehringer-Ingelheim-funded study supports the use of pimobendan in patients with Stage B2 MMVD.4 It is important to note that the dogs included in the study had to meet specific criteria, including both radiographic and echocardiographic evidence of heart enlargement.

Because not all patients will have access to echocardiography, and given the breed variability and potential low accuracy of using only VHS for assessment of heart enlargement, broader diagnostic requirements have been proposed to help practitioners determine when to initiate therapy in dogs with Stage B2 MMVD.5 These recommendations suggest that pimobendan be considered for dogs that meet the following criteria: 5

  • Asymptomatic small breed dog

  • Heart murmur characteristic of mitral regurgitation; at least 3/6 or greater

  • VHS ≥ 11.5; or progression of heart size of ≥ 0.5 VHS units over a six-month period.

While early intervention in this subset of patients appears to prolong the time to onset of CHF, careful patient selection will be required to determine whether pimobendan treatment will be of benefit.

Link to studies:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115200/

http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2009.0392.x/full

http://www.vetsmall.theclinics.com/article/S0195-5616(17)30036-0/fulltext

References

1. Buchanan JW. Prevalence of cardiovascular disorders In: Fox PR, editor; Sisson D, editor; Moise NS, editor. eds. Textbook of Canine and Feline Cardiology. Philadelphia: Saunders, W.B.; 1999:457–470.

2. Egenvall A, Bonnett BN, Hedhammar A, et al. Mortality in over 350,000 insured Swedish dogs from 1995-2000: II. Breed-specific age and survival patterns and relative risk for causes of death. Acta Vet Scand 2005;46:121–136.

3. Atkins C, Bonagura J, Ettinger S et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009;23(6):1142-1150.

4. Boswood A, Häggström J, Gordon SG et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC study-a randomized clinical trial. J Vet Intern Med 2016;30(6):1765-1179.  

5. Gordon SG, Saunders AB, Wesselowski SR. Asymptomatic canine degenerative valve disease: current and future therapies. Vet Clin North Am Small Anim Pract. 2017;47(5):955-975.

Related Content:

MedicalAssociatesCardiologySurgeryTechniciansEmergency & Critical Care
UC Davis oral surgeons repair kitten’s severe cleft palate
UC Davis oral surgeons repair kitten’s severe cleft palate
Tips and tricks for diagnosing canine osteoarthritis early
Tips and tricks for diagnosing canine osteoarthritis early
Performing surgery on dogs with GDV
Performing surgery on dogs with GDV

Advertisement

Latest News

Morris Animal Foundation appoints new chief program officer

CDC issues warning over cat-transmitted sporotrichosis

An AI solution is speeding up insurance claims processing

3 categories of inappetence in dogs

View More Latest News
Advertisement